Linezolid versus vancomycin for skin and soft tissue infections

Evidence-Based Child Health

Volumn 9, Issue 1, 2014, Pages 103-166

  Yue, Jirong ^a   Dong, Bi Rong ^a   Yang, Ming ^a   Chen, Xiaomei ^a   Wu, Taixiang ^a   Liu, Guan J ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Acetamides adverse effects; ; Anti Bacterial Agents adverse effects; ; Drug Eruptions etiology; Drug therapy; Length of Stay; Oxazolidinones adverse effects; ; Pruritus chemically induced; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Soft Tissue Infections; Therapeutic use; Thrombocytopenia chemically induced; Vancomycin adverse effects;

Indexed keywords

CEPHALOSPORIN; CLINDAMYCIN; LINEZOLID; PENICILLIN DERIVATIVE; VANCOMYCIN;

ALLERGIC REACTION; ARTICLE; BONE MARROW SUPPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ERYTHRODERMA; HOSPITALIZATION; HUMAN; INCIDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; NAUSEA; NEPHROTOXICITY; OTOTOXICITY; OUTPATIENT CARE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK ASSESSMENT; SKIN INFECTION; SOFT TISSUE INFECTION; THROMBOCYTOPENIA;

EID: 84896455516     PISSN: None     EISSN: 15576272     Source Type: Journal    
DOI: 10.1002/ebch.1961     Document Type: Article

References (116)

1. References to studies included in this review
2. Itani 2010 {published data only}
3. Itani KM, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, Weigelt JA. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. American Journal of Surgery 2010;199(6):804-16.
4. Jaksic 2006 {published data only}
5. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases 2006;42(5):597-607.
6. Kohno 2007 {published data only}
7. Kohno S, Yamaguchi K, Aikawa N, Sumiyama Y, Odagiri S, Aoki N, et al.Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy 2007;60(6):1361-9.
8. Lin 2008 {published data only}
9. Lin DF, Wu JF, Zhang YY, Zheng JC, Miao JZ, Zheng LY, et al.A randomized, double-blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy 2009;9(1):10-7.
10. * Lin Df, Zhang YY, Wu JF, Wang F, Zheng JC, Miao JZ, et al.Linezolid for the treatment of infections caused by Gram-positive pathogens in China. International Journal of Antimicrobial Agents 2008;32(3):241-9.
11. Sharpe 2005 {published data only}
12. Sharpe JN, Shively EH, Polk HC. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. American Journal of Surgery 2005;189(4):425-8.
13. Stevens 2002 {published data only}
14. Li JZ, Willke RJ, Rittenhouse BE. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surgical Infections 2003;4(1):57-70.
15. Li Z, Willke RJ, Pinto LA, Rittenhouse BE, Rybak MJ, Pleil AM, et al.Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001;21(3):263-74.
16. * Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clinical Infectious Diseases 2002;34(11):1481-90.
17. Weigelt 2005 {published data only}
18. Itani KM, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents 2005;26(6):442-8.
19. McCollum M, Sorensen SV, Liu LZ. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics 2007;29(3):469-77.
20. McKinnon PS, Sorensen SV, Liu LZ, Itani KM. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Annals of pharmacotherapy 2006;40(6):1017-23.
21. * Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C, et al.Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy 2005;49(6):2260-6.
22. Weigelt J, Kaafarani HM, Itani KM, Swanson RN. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. American Journal of Surgery 2004;188(6):760-6.
23. Wilcox 2009 {published data only}
24. Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Ljzerman MM. Complicated skin and skin-structure infections and catheter-related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases 2009;48(2):203-12.
25. Yogev 2003 {published data only}
26. Deville JG, Adler S, Azimi PH, Jantausch BA, Morfin MR, Beltran S, et al.Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal 2003;22(9 suppl):S158-63.
27. Kaplan SL, Afghani B, Lopez P, Wu E, Fleishaker D, Edge-Padbury B, et al.Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal 2003;22(9 Suppl):S178-85.
28. *Yogev R, Patterson LE, Kaplan SL, Adler S, Morfin MR, Martin A, et al.Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal 2003;22(9 SUPPL):S172-7.
29. References to studies excluded from this review
30. Bounthavong 2009 {published data only}
31. Bounthavong M, Hsu DI, Okamoto MP. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model. International Journal of Clinical Practice 2009;63(3):376-86.
32. Hau 2002 {published data only}
33. Hau T. Efficacy and safety of linezolid in the treatment of skin and soft tissue infections. European Journal of Clinical Microbiology and Infectious Diseases 2002;21(7):491-8.
34. Joseph 2007 {published data only}
35. Joseph WS. Commentary on Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Foot and Ankle Quarterly--The Seminar Journal 2007;19(1):26-8.
36. Kalil 2006 {published data only}
37. Kalil AC, Puumala S, Stoner J. Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus? comment. Antimicrobial Agents and Chemotherapy 2006;50(5):1910.
38. Lipsky 2011 {published data only}
39. Lipsky BA, Itani KM, Weigelt JA, Joseph W, Paap CM, Reisman A, et al.The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: results from three randomized controlled trials. International Journal of Infectious Diseases 2011;15(2):e140-6.
40. McKinnon 2007 {published data only}
41. McKinnon PS, Carter CT, Girase PG, Liu LZ, Carmeli Y. Health economics. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective. Managed Care Interface 2007;20(1):23-34.
42. Patanwala 2007 {published data only}
43. Patanwala AE, Erstad BL, Nix DE. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections. Current Medical Research and Opinion 2007;23(1):185-93.
44. Schurmann 2009 {published data only}
45. Schurmann D, Sorensen SV, De Cock E, Duttagupta S, Resch A. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany. European Journal of Health Economics 2009;10(1):65-79.
46. Additional references
47. Beibei 2010
48. Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, Rui W. Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. International Journal of Antimicrobial Agents 2010;35(1):3-12.
49. Bounthavong 2010
50. Bounthavong M, Hsu DI. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): A meta-analysis. Current Medical Research and Opinion 2010;26(2):407-21.
51. Bouza 2004
52. Bouza E, Sousa D, Muñoz P, Rodríguez-Créixems M, Fron C, Lechuz JG. Bloodstream infections: a trial of the impact of different methods of reporting positive blood culture results. Journal of Infectious Diseases 2004;39(8):1161-9.
53. Deeks 2011
54. Deeks JJ, Higgins JPT, Altman DG, on behalf of theCochrane Statistical Methods Group and the CochraneBias Methods Group (Editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
55. Dickersin 1990
56. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 1990;263(10):1385.
57. Dodds 2009
58. Dodds TJ, Hawke CI. Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis). ANZ Journal of Surgery 2009;79(9):629-35.
59. Donner 2001
60. Donner A, Piaggio G, Villar J. Statistical methods for the meta analysis of cluster randomization trials. Statistical Methods in Medical Research 2001;10(5):325-38.
61. Eisenstein 2008
62. Eisenstein BI. Treatment challenges in the management of complicated skin and soft-tissue infections. Clinical Microbiology and Infection 2008;14(Suppl 2):17-25.
63. Engemann 2003
64. Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL, et al.Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clinical Infectious Diseases 2003;36(5):592-8.
65. Eron 2003
66. Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA. Managing skin and soft tissue infections: expert panel recommendations on key decision points. Journal of Antimicrobial Chemotherapy 2003;52(Suppl 1):i3-i17.
67. Falagas 2008
68. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infectious Diseases 2008;8(1):53-66.
69. FDA 1998
70. FDA Uncomplicated and complicated skin and skin structure infections--developing antimicrobial drugs for treatment. Guidance for Industry: Center for Drug Evaluation and Research (CDER). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071185.pdf 1998.
71. Finch 2005
72. Finch RG, Eliopoulos GM. Safety and efficacy of glycopeptide antibiotics. Journal of Antimicrobial Chemotherapy 2005;55(Suppl 2):ii5-ii13.
73. Fritsche 2007
74. Fritsche TR, Sader HS, Jones RN. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Diagnostic Microbiology and Infectious Disease 2007;58(1):19-26.
75. Fung 2001
76. Fung HB, Kirschenbaum HL, Ojofeitimi BO. Linezolid: an oxazolidinone antimicrobial agent. Clinical Therapeutics 2001;23(3):356-91.
77. Fung 2003
78. Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 2003;63(14):1459-80.
79. Higgins 2003
80. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
81. Higgins 2011a
82. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
83. Higgins 2011b
84. Higgins JPT, Green S (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
85. Jones 2009
86. Jones RN, Ross JE, Bell JM, Utsuki U, Fumiaki I, Kobayashi I, et al.Zyvox(R) Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Diagnostic microbiology and infectious disease 2009;65(4):404-13.
87. Kollef 2004
88. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Medicine 2004;30(3):388-94.
89. Lamagni 2008
90. Lamagni TL, Darenberg J, Luca-Harari B, Siljander T, Efstratiou A, Henriques-Normark B, et al.Epidemiology of severe Streptococcus pyogenes disease in Europe. Journal of Clinical Microbiology 2008;46(7):2359-67.
91. Lefebvre 2011
92. Lefebvre C, Manheimer E, Glanville J, on behalf of the Cochrane Information Retrieval Methods Group. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
93. Levine 2006
94. Levine DP. Vancomycin: a history. Clinical Infectious Diseases 2006;42(Supplement 1):S5.
95. Moellering 1999
96. Moellering RC Jr. A novel antimicrobial agent joins the battle against resistant bacteria. Annals of Internal Medicine 1999;130(2):155-7.
97. Moet 2006
98. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagnostic Microbiology and Infectious Disease 2007;57(1):7-13.
99. Pallares 1993
100. Pallares R, Dick R, Wenzel RP, Adams JR, Nettleman MD. Trends in antimicrobial utilization at a tertiary teaching hospital during a15-year period (1978-1992). Infection Control and Hospital Epidemiology 1993;14(7):376-82.
101. Schulz 1995
102. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
103. Shorr 2005
104. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. Journal of Antimicrobial Chemotherapy 2005;56(5):923.
105. SIGN 2008
106. Scottish Intercollegiate Guidelines Network (SIGN). Search filters. http://www.sign.ac.uk/methodology/filters.html#random (accessed 27 May 2008).
107. Sivagnanam 2003
108. Sivagnanam S, Deleu D. Red man syndrome. Critical Care 2003;7(2):119-20.
109. Stevens 2005
110. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, et al.Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clinical Infectious Diseases 2005;41(10):1373-406.
111. Tsiodras 2001
112. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al.Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358(9277):207-8.
113. Wilson 2008
114. Wilson DN, Schluenzen F, Harms JM, Starosta AL, Connell SR, Fucini P. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proceedings of the National Academy of Sciences 2008;105(36):13339.
115. Wunderink 2003
116. Wunderink RG, Rello J, Cammarata S, Croos-Dabrera RV, KollefMH Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124(5):1789-97.